


NuGen Medical Devices provide easy and painless injections without needles

Having spent far too much time over the last two years watching Netflix, reading fiction and playing video games, it has become apparent to me that my brain is starting to blur the lines between reality and fantasy. As I started doing my homework for today's company and their needle-free injection technology, I was thinking what's the big deal. I've seen that for decades now, at least on Star Trek. Then I started to think about it a little more. I've never had a needle free injection, nor has it ever been an option for me. I've also never spoken to, or even heard of anyone getting a needle free injection. All of sudden it dawned on me that something I just assumed was already "a thing", was instead leading-edge science and also pretty awesome.

The company with this cool technology is NuGen Medical Devices Inc. (TSXV: NGMD). The Company's principal business is the development and commercialization of innovative needle-free injection devices and systems for the administration of subcutaneous medication. It is developing products using needle-free drug delivery technology in several important fields including, but not limited to, anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, psoriasis as well as DNA and conventional/pediatric vaccines. Their flagship product – InsuJet™ is a revolutionary needle-free drug delivery device, used to self-administer medication in a safe, fear-free, and virtually pain-free manner and is now approved for use in over 40 countries globally.

Explaining how it works may seem somewhat obvious, but because

we're talking about science fiction becoming reality, I'm going to do it anyway. The liquid drug is inserted into the NuGen device, which uses a simple, but powerful, spring-loaded mechanism. Pressure is built up and releases the drug as a fine jet stream of liquid, traveling fast enough to penetrate the skin via a microscopic entrance. In less than one-tenth of a second, the drug is dispensed more safely and evenly compared to needle syringes. It's also virtually painless and leaves no mark on the skin. The graphic below also depicts how the medication is more evenly distributed. If you want to see a video animation of this, here is a link for readers.



Source: NuGen Medical Devices Corporate Presentation

As you can probably guess from the name (InsuJet™), the original focus was on serving insulin dependent diabetic

patients. Diabetics manage blood sugar levels through daily administration of insulin, often three to four times per day. Aside from making life more convenient and cost effective for diabetics, this market becomes obvious when you look at the statistics. Diabetes has become one of the leading causes of deaths worldwide. According to the World Health Organization, around 1.5 million people worldwide died due to diabetes in 2019. It is estimated that 463 million people are living with diabetes all over the world and by 2045, projections show this number rising to some 700 million diabetics globally. Sadly, it doesn't stop there. According to Diabetes Canada, complications related to diabetes are serious and can be life-threatening. Annually, people living with diabetes account for:

- 30% of strokes;
- 40% of heart attacks;
- 50% of kidney failure requiring dialysis; and,
- 70% of non-traumatic amputations.

It becomes readily apparent that it is a 'no-brainer' for this device to become a primary tool for improving the lives of diabetics. But to me, that's just the beginning. Having just seen the world administer billions of COVID vaccines, and thinking about all the single use needles that went along with that, I have to think the InsuJet™ would make for a way better solution on that front as well. And I'm not the only one thinking that way. The Company just signed a landmark partnership deal with Unifire Inc. to market and distribute its needle-free injection device to United States Government agencies.

Mr. Douglas Bryce, Former Joint Program Executive Officer for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) for the US Army is quoted in the press release as saying "The disruptive nature of the needle-free injection solution to improve the standard of care for members and the general public cannot be understated. The safe, rapid, and

effective delivery of medication through this device are within the mandates of the government to improve care, reduce waste and lower costs. As such, I believe there is significant opportunity within the Department of Defense and Military operated medical facilities as well as inclusion within the casual combat care packages, global vaccination efforts and many others.” There you have it from someone with way more credibility than me.

I believe this is the logical evolution of injecting anything into your body, and not just because I saw it on Star Trek (well maybe a little). The addressable market is enormous. However, we’ll have to wait and see how things progress for NuGen Medical Devices as they’ve only been trading publicly since November, 2021 and thus far have no representative quarterly results. What I do know is they have a market cap of roughly C\$22 million which means there could be some significant upside if the world demands their next vaccination or injection be needleless.

How NASDAQ listed Zentek is a ‘wow’ company with enormous potential to tap into several multi-billion dollar industries.

Every once in a while investors will come across a ‘wow’ company. This is a company that just wows you with their performance and their stock price.

For me the 'wow' company of the last year is Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN). Just take a look at the stock chart below, showing the stock rising a staggering 9.7x over the past approximately year and a half. The good news for investors is that the recent pullback allows for a better entry price than when the stock peaked at C\$6.50.

Zentek Ltd (TSXV: ZEN) 5 year stock price chart



Source: Yahoo Finance

Today I give a brief summary of Zentek for new investors and an update on their progress in 2022.

Zentek's business summary

Zentek describe themselves as "an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment." I prefer to think of them as a nanotechnology and graphene company (they were formerly known as ZEN Graphene Solutions) that has expanded into multiple areas of commercialization; particularly into the healthcare sector

with a product for prevention, detection and treatment of numerous pathogens.

Areas/products of commercialization for Zentek include:

- **ZenGUARD™** – A patent-pending ‘graphene-silver coating’ shown to have 99% antimicrobial activity, including against COVID-19. The coating can be used for PPE applications (including nitrile gloves, gowns, footwear coverings and surgical caps) and also in air purifiers. According to Zentek: “ZenGUARD™-coated masks removed 98.9% more bacteria and 97.8% more virus compared to a typical ASTM Level 3, 3-ply uncoated, resulting in over 99.99% BFE and VFE ratings.” ZenGUARD™ has Health Canada approval (Medical Device Establishment License, “MDEL”) and production facilities are being readied for first orders. Zentek is commercializing ZENGuard™ with mask manufacturer Trebor Rx, but can also work with other manufacturers.
- **Pathogen Detection Technology** (aptamer-enabled) – A low cost, rapid, saliva testing, scalable technology to detect numerous pathogens, initially to be used for COVID-19 testing.
- **Antimicrobial therapies** – In-vitro testing shows 99.9% effectiveness against bacteria, fungi and viruses.
- **Air conditioner filter coating** – Zentek has experimented with past partners to use graphene oxide coated filters to help remove moisture from the air and make air conditioners up to 75% more energy efficient.
- **Icephobic graphene coatings** – Potential to significantly increase safety for vehicles such as drones, aircraft, ocean vessels, wind turbines, and other applications where, in cold weather climates, there is the potential for ice to accrete on surfaces. An ‘icephobic’ surface repels ice build up.
- **Others** – Graphene tires, graphene in concrete, fuel additives (potential to reduce GHG emissions from diesel

and bio-diesel fuels by as much as 10%), and graphene for batteries.

Zentek's latest news and progress in 2022

Zentek announced on February 18, 2022 the development of graphene-wrapped silicon anodes. Zentek CEO Greg Fenton stated: "Not only were the researchers able to demonstrate good performance with laboratory-scale half-cells, the performance was also validated with commercial lithium iron phosphate cathodes suggesting they could be a drop-in solution for enhancing already available battery technologies. We look forward to continuing our support of their research and development to potentially bring this technology to market. The company has begun discussions with a potential industry partner."

As reported on February 28, 2022, Zentek's Guelph production facility is now fully licensed and permitted for ZenGUARD™ production and substantially all equipment has been received to ramp-up industrial scale capacity. First orders have been received and the ZenGUARD™ international patent is due shortly. As reported on January 13, Zentek has entered into a binding letter of intent with GMAF Circular Medico ApS to produce and sell ZENGuard™-enhanced GMAF trademarked recyclable surgical masks.

With regards to the Pathogen Detection Technology, Zentek continues to work to bring the product to market as soon as practicable, which will require having a working prototype prepared, having conducted baseline studies, and having made applications to regulatory bodies.

With regards to Zentek's icephobic coatings, they are currently undergoing full flight trials on a specially equipped research aircraft under real world ice-forming weather conditions.

Zentek's new manufacturing facility in Guelph, Ontario, Canada

is set for commissioning shortly

Manufacturing Centre

1123 York Rd,
Guelph, Ontario, N1E 6Z1

Zentek's Manufacturing Centre is 25,680 square feet of a newly built industrial zoning space in Guelph, Ontario. Zentek has successful ramp up from bench scale production to pilot scale capacity, which currently exceeds the amount required to coat 30 million masks per month. The engineering work on Zentek's industrial plant, which has an estimated capacity to coat the equivalent of 800 million masks per month, is completed and is now in the procurement stage. Zentek expects the build out, and commissioning of the plant will be completed during Q1, 2022. This facility will give us the scale we need for our current obligations and for the demand we expect to have in the future.



Source: Zentek website

Closing remarks

Zentek really is a 'wow' company with enormous potential to tap into several multi-billion dollar industries. Focusing on pathogens (viruses, bacteria, fungi) prevention, detection, and treatment is simply staggering. Then there are multiple other applications for Zentek's products, the most recent being graphene-wrapped silicon anodes that can potentially be used to create better EV batteries and the icephobic coatings opportunity.

In terms of commercialization, Zentek is already advancing with ZenGUARD™ in terms of a production facility and orders, with the ZenGUARD™ patent due very soon and production from Zentek's new Guelph facility set to begin very soon.

Finally, Zentek is now getting the exposure it deserves with a NASDAQ listing that began on March 22, 2022, under the ticker "ZTEK". Not surprisingly the stock rose 25.93% on March 23.

Zentek has C\$32 million in cash, no debt, and looks like being a 'wow' company again in 2022. Stay tuned.

Disclosure: The author is long Zentek (TSXV: ZEN).

Dr Jon Gluckman provides an update on Sixth Wave Innovations' pathogen detection technologies

In a recent InvestorIntel interview, Tracy Weslosky spoke with Dr. Jon Gluckman, President and CEO of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: SIXWF) about Sixth Wave's virus detection technology for SARS-CoV-2 and about their partnership with TraceSafe Inc. for the detection of viruses and pathogens in animals.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Gluckman said that Sixth Wave's virus detection technology is based on molecular imprinted polymer and "...can detect the COVID-19 virus and all its variants, at levels that are better than immunoassay tests." He went on to highlight the growing instances of disease outbreaks in animals caused by viruses and pathogens that can impact our food supplies. Dr. Gluckman also explained how Sixth Wave is working with TraceSafe to develop a first-of-its-kind solution that can prevent and contain deadly viruses and pathogens in animals and provide real-time updates across the entire food supply chain.

To watch the full interview, click here

About Sixth Wave Innovations Inc.

Sixth Wave is a development stage nanotechnology company with patented technologies that focus on extraction, purification, and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of commercializing its, IXOS[®], a line of extraction polymers for the gold mining industry.

Sixth Wave can design, develop, and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection, purification, and separation of viruses, biogenic amines and other pathogens, and nutraceuticals for which the Company has products at various stages of development.

To learn more about Sixth Wave Innovations Inc., [click here](#)

Disclaimer: *Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the

Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

Jon Gluckman of Sixth Wave Innovations on the increased profitability and decreased carbon emissions from gold mines using its IXOS® product line

In a recent InvestorIntel interview, Tracy Weslosky spoke with Dr. Jon Gluckman, President and CEO of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: SIXWF) about how Sixth Wave's IXOS® gold adsorption and recovery technology can help reduce costs and increase yield for gold mines resulting in as much as

US\$100/Troy Oz savings.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Gluckman said that Sixth Wave's IXOS® purification polymer is eco-friendly and is a superior replacement for the activated carbon used today in the gold mining industry. He went on to explain how IXOS® can provide additional carbon credits for reducing carbon dioxide emissions and help enhance a gold mine's ESG posture. Currently working with some of the major gold mining companies, Dr. Gluckman said that Sixth Wave's IXOS® technology can also be used in silver mining and in that of other high value metals.

To watch the full interview, click here

About Sixth Wave Innovations Inc.

Sixth Wave is a development stage nanotechnology company with patented technologies that focus on extraction, purification, and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of commercializing its, IXOS®, a line of extraction polymers for the gold mining industry.

Sixth Wave can design, develop, and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection, purification, and separation of viruses, biogenic amines and other pathogens, and nutraceuticals for which the Company has products at various stages of development.

To learn more about Sixth Wave Innovations Inc., click here

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

Zentek responds to naysayers and asks “What’s all the fuss about?”

The dreaded “short report” is an article or research report that focusses on anything and everything negative about a company and tries to make it sound like the most inept or corrupt organization on the planet, typically for the benefit of the author and their acquaintances. Granted in some instances analysis of this type is warranted, but in many cases it’s more of an attempt to make a mountain out of a mole hill and take advantage of “weak” shareholders. By that I mean investors who don’t read each quarterly MD&A, the latest corporate presentation, or Annual Information Form and who could get spooked by what sounds like a legitimate negative case without fully understanding the positive case which led them to invest in the first place. I will give short report authors credit as they typically have done plenty of homework and likely know a lot more about what’s going on in a company than the average long investor, but it isn’t always the fairest representation of a company.

Zentek Ltd. (TSXV: ZEN | OTC: ZENYF) was recently on the receiving end of one of these critical reviews. As a reminder, Zentek (formerly known as ZEN Graphene Solutions Ltd.) is an IP development and commercialization company that uses expertise in nanomaterials and strategic partnerships to break through the barriers of molecular science and uncover new possibilities in healthcare and beyond. The Company is focused on next-gen healthcare solutions in the areas of prevention, detection and treatment.

The report in question was posted on Seeking Alpha early last week and led to a pretty wild day of trading with a 36% price swing from high to low, although the stock ultimately closed

higher than the day before the report was published. I've read through the Seeking Alpha report and there's some speculation in there that challenges the imagination a bit. Other parts are simply portraying the glass as half empty, so to speak, versus half full. However, the key issue that caused the frothy trading on March 8th, in my opinion, is related to a lawsuit filed against Zentek over a year ago that the Company hadn't disclosed anywhere. They addressed the issue in press releases on March 8th and further on March 9th.

Critically, Zentek states "As disclosed March 8, 2022, ZEN received a statement of claim from Graphene Composites Ltd. ("GC") on January 29, 2021, for breach of confidentiality. The Company maintains that this claim is frivolous based on the fact the information shared by GC was already in the public domain. This position is supported by the public examiner's response to Graphene Composites patent application #3,097,636 on April 27, 2021, where the examiner rejected 107 out of 108 claims made by Graphene Composites." To me it's a bit of a misstep to not get out in front of this from the get go and control the narrative. If they had press released the above quote in April, 2021 (regardless of whether it was thought to be frivolous or immaterial) instead of last week then perhaps all of this uncertainty could have been avoided. Hopefully, the lesson has been learned going forward.

The report of which we are speaking goes on to challenge the production and sales projections of ZenGUARD™ coated masks, especially in light of more recent developments where many major jurisdictions around the world are either reducing or eliminating mask mandates. The author is entitled to their opinion on this but arguably the world has changed somewhat over the last year, and all shareholders can make their own assessment on this topic. To me this is an example of focusing on the glass half empty. Perhaps the Company has over-promised and/or under-delivered with respect to ZenGUARD™ in the past but as I've noted, the last year has been the epitome of a

moving target. It's easy to criticize in hindsight.

Regardless of what I think or say, or the opinion of the Seeking Alpha report, as an investor you have to look forward and decide if the stock price today is warranted and if there is upside in the future. Despite the recent disclosure of a year old legal proceeding, the Company has addressed this issue to my satisfaction, so it is a non-issue to me going forward. It raised C\$33 M in January and has a quarterly cash burn rate of roughly C\$2-C\$2.5 M per quarter (and no debt), so they are fine for available working capital. They have several business segments being pursued, of which ZenGUARD™ actually started generating revenue in the final quarter of 2021. Now the onus is on you as an investor to decide if Zentek is worth its C\$292 M market cap.

Greg Fenton and Byron King discuss Zentek's highly innovative graphene Icephobic coatings for aircraft and wind turbine lifetime and safety improvement

In a recent InvestorIntel interview, Byron King spoke with Greg Fenton, CEO and Director of Zentek Ltd. (TSXV: ZEN) about the results from testing on Zentek's Icephobic coating that provides an effective de-icing and anti-icing solution for drone and wind turbine markets and about Zentek's "imminent" listing on the Nasdaq.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg Fenton highlighted the application of Zentek's icephobic coating in aviation, drones, powerlines and wind turbines and explained how it can improve safety and efficiency while retaining its icephobic properties for years. Speaking about the next step of testing Zentek's icephobic coating for sand and rain erosion, Greg pointed out how Zentek plans to take its products to the marketplace without having to incur huge capital expenditure.

To watch the full interview, click here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing Zen**GUARD**[™], a patent-pending coating shown to have 99% effectiveness in antimicrobial activity reduction, including against the COVID-19 pathogens, and the potential to use similar compounds as products against other infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed rapid aptamer-based pathogen detection technology.

To learn more about Zentek Ltd., click here.

Disclaimer: *Zentek Ltd. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements"

within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

Greg Fenton on Zentek's approval for Nasdaq listing and the expanding use of its

highly effective anti-microbial ZenGUARD™ coating

In a recent InvestorIntel interview, Tracy Weslosky spoke with Greg Fenton, CEO and Director of Zentek Ltd. (TSXV: ZEN) about Zentek's recent news release on receiving approval to list on the Nasdaq and about engaging Vimta Labs to begin studies of ZenGUARD™ active ingredient as a potential treatment of infectious skin disease.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg Fenton provided an update on Zentek's "unique and innovative" ZenGUARD™ antimicrobial coating which is "proven to be more than 99% effective in reducing the physical spread of the SARS-CoV-2" and other pathogens. He went on to say that Zentek will be publishing the patent application for the ZenGUARD™ antimicrobial coating on March 21, 2022.

To watch the full interview, click here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% effectiveness in antimicrobial activity reduction, including against the COVID-19 pathogens, and the potential to use similar compounds as products against other infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed rapid aptamer-based pathogen detection technology.

To learn more about Zentek Ltd., click here.

Disclaimer: Zentek Ltd. is an advertorial member of

InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

NuGen Medical Devices advances its needle-free, pain-free, drug delivery system worldwide


No more needles needed for vaccines, diabetes and everyday medicine delivery

Do you know anyone who likes injections? Well today there is a new innovative and better way to administer medicines.

Injections are a common healthcare procedure, administered to billions every day, but now the technique is increasingly going needle-free. Needle-free delivery has many advantages over needles, including: Faster absorption of medicine, safer (eliminates cross-contamination), less expensive, sustainable (less waste), and reduced patient anxiety and fear.

The global needle-free injection market is forecast to grow at a CAGR of 16.3% from US\$11.8 billion in 2020 to US\$25 billion in 2025

GLOBAL MARKET OPPORTUNITY



Source: NuGen Medical Devices company presentation

Today's company is focused on 'revolutionizing needle-free delivery'.

NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen") is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. The company commercializes a Health Canada and CE approved 'needle-free injection' system (known as "InsuJet™") catering to a wide range of applications.

NuGen state: "NuGen's needle-free injection system is the first ever self-administered needle-free injection system approved by Health Canada and gives access to safe, cost-effective drug delivery for the millions of patients who suffer from diabetes or other chronic illnesses."

NuGen's needle-free injection systems have almost unlimited uses in modern medicine. One of the most common is for diabetes management where children often need to inject themselves with insulin several times a day. Another common use is at the medical clinic where a doctor delivers a vaccine or medicine, or perhaps a COVID-19 booster. Other examples are

IVF (Intravenous Feeding) treatments, human growth hormone treatments and so on.

NuGen's needle-free product "InsuJet™" and how it works

The infographic is divided into two main sections. On the left, a blue and white NuGen handheld device is shown. The right side is titled "HOW IT WORKS" and contains two diagrams. The first diagram, labeled "NEEDLE-FREE", shows a device on top of a skin cross-section. A blue cone of micro-droplets penetrates the skin, spreading out in a honeycomb pattern. The second diagram, labeled "NEEDLE", shows a traditional syringe with a needle inserted into the skin. A blue droplet is shown pooling at the bottom of the needle. Text above the diagrams explains that high-pressure jet injections dispense micro-droplets evenly, while traditional syringes cause medication to pool over time.

The company has perfected its needle-free devices, which are now available for commercialization in over 40 countries.

HOW IT WORKS

High-pressure jet injections dispense micro-droplets of medication evenly into the skin.

Traditional needle syringes penetrate the skin, causing medication to pool over time.

NEEDLE-FREE

NEEDLE

NuGen's Nanojex device works by painlessly delivering medicines through the skin, using a gas jet to accelerate powdered nanoparticles of drug or protein to supersonic speed with a single-use, disposable, handheld device.

Examples of uses for NuGen's needle-free 'Nanojex'



THERMOSTABLE

New powder drug formulation will eliminate the cold chain

IMPROVED EFFICACY

Demonstrated possible dose reduction for conventional and DNA vaccines

CONTROLLED RELEASE

Encapsulation offers the possibility of time-released drug delivery

Source: NuGen Medical Devices company presentation

Global approval and rollout of NuGen's products

NuGen Medical Devices have achieved multiple regulatory approvals, and the company is cleared to sell its devices in over 40 countries, including Health Canada approval.

NuGen has already signed multiple sales and distribution agreements. Some recent examples include:

- Feb. 1, 2022 – “InsuJet™ Needleless Injection Devices to administer “Insulin Without Fear” for Children with Diabetes in Taiwan.”
- Jan 18, 2022 – “NuGen M.D. announces a \$333,000 5-year distribution agreement with Intermediq for its InsuJet™ Needle-Free Injection Device.”
- Nov. 30, 2021 – “NuGen Announces a \$5.8 million, 5-Year

Distribution Agreement with Khotwa Medical Co. for its InsuJet Needle Free Injection Device and accessories.”

Management, board and advisors

NuGen spent 2021 getting product approvals and growing their management team and advisers. It is now an experienced and extensive team as you can view here on pages 12 & 13. Inside ownership stands at an impressive 20.8%.

Next steps

2022 looks set to be a big year for NuGen. NuGen states their 2022 objectives as follows:

- “Secure additional global distribution and sales agreements with minimum yearly commitments for its needle-free injection device and consumables.
- **Supply a minimum 8,000 needle-free injection systems into the global market**, generating one-time revenue for the device in addition to the recurring revenue of the consumables over the expected lifetime of a device (~3 to 5 years), both important revenue streams to the Company.
- Submit for regulatory approvals in other key markets with high demand for our product line.
- Continue to monitor the market for potential M&A opportunities in an effort to rapidly grow its sales and position itself as the global leader in needle-free injection technology.
- Continue R&D on our next generation Needle-Free injection technologies.
- Capitalize on the opportunity in the animal market to give pet owners access to safe, fear-free and virtually painless injections for their pets.”

Note: Bold highlight by the author.

Closing remarks

NuGen is now entering the stage of development of ramping up global sales and revenues. This means 2022 will be the most important year to date for NuGen. The product looks to be a winner, approvals and some distributions are in place. We will check back after some months to see how sales and revenues are performing.

NuGen Medical Devices trades on a market cap of only C\$20 million. One to watch.

Steve Saviuk of Valeo Pharma on record 2021 revenues, achieving breakeven in 2022, and uplisting on the TSX

In a recent InvestorIntel interview, Tracy Weslosky spoke with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF) about Valeo's recent news release reporting record revenues for Fiscal 2021, up 81% over 2020.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Steve Saviuk said that Valeo is a revenue generating commercial stage company currently undergoing significant growth. With world-class products and a strong management team with a history of success, Steve said that the stage is set for Valeo to drive stronger revenue growth in the coming quarters as Valeo targets uplisting on TSX. Steve went on to highlight the success Valeo has achieved in obtaining Public Reimbursement for Redesca™ and two innovative Asthma therapies as provinces in Canada are increasingly agreeing to pay for

them.

To watch the full interview, [click here](#).

About Valeo Pharma Inc.

About Valeo Pharma Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., [click here](#).

Disclaimer: *Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

Mike Druhan of MedX Health on the Launch of Its Teledermatology Screening Platform in the UK

In a recent InvestorIntel interview, Tracy Weslosky spoke with Mike Druhan, President of Dermatology Services at MedX Health Corp. (TSXV: MDX) about MedX Health's recent commercialization pilot project with the UK's largest non-hospital private healthcare services provider to launch its Teledermatology Screening Platform in the UK.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Mike Druhan explained how the partnership with Health Partners (OH) Limited will provide MedX access to two

million-plus patients across the UK and also will open the door for MedX Health to expand into other markets. With more than 3,000 cases of skin cancer annually in the construction industry in the UK alone, Mike went on to highlight how early detection of skin cancers can have a dramatic effect in saving people's lives and play a critical role in the fight against skin cancer.

To watch the full interview, [click here](#)

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey.

To learn more about MedX Health Corp., [click here](#).

Disclaimer: MedX Health Corp. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this

interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.